Elevance Health (ELV)
Market Price (12/29/2025): $350.0 | Market Cap: $78.2 BilSector: Health Care | Industry: Managed Health Care
Elevance Health (ELV)
Market Price (12/29/2025): $350.0Market Cap: $78.2 BilSector: Health CareIndustry: Managed Health Care
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.0%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.9% | Weak multi-year price returns2Y Excs Rtn is -68%, 3Y Excs Rtn is -109% | Key risksELV key risks include [1] margin pressure from rising medical costs within its Medicare and Medicaid plans, Show more. |
| Attractive cash flow generationCFO LTM is 4.9 Bil, FCF LTM is 3.8 Bil | ||
| Low stock price volatilityVol 12M is 36% | ||
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.0%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.9% |
| Attractive cash flow generationCFO LTM is 4.9 Bil, FCF LTM is 3.8 Bil |
| Low stock price volatilityVol 12M is 36% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -68%, 3Y Excs Rtn is -109% |
| Key risksELV key risks include [1] margin pressure from rising medical costs within its Medicare and Medicaid plans, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
1. Strong Q3 2025 Financial Performance: Elevance Health's third-quarter 2025 earnings comfortably surpassed Wall Street expectations, with reported earnings per share of $6.03 against an anticipated $5.03, and revenue of $50.09 billion, exceeding estimates by growing 12% year-over-year. This positive financial report likely contributed to an upward movement in the stock.
2. Strategic Restructuring of Medicare and Part D Plans and Revised EPS Outlook: In September 2025, Elevance Health announced a strategic decision to exit the standalone Part D program and reduce its presence in unprofitable Medicare Advantage plans, a move impacting hundreds of thousands of members. This strategic shift, while aimed at long-term profitability, also led to a revised and lower 2025 earnings per share outlook of approximately $30, down from the previous range of $34.15-$34.85, primarily due to rising medical costs. These announcements likely introduced volatility and downward pressure on the stock.
Show more
Stock Movement Drivers
Fundamental Drivers
The 10.4% change in ELV stock from 9/28/2025 to 12/28/2025 was primarily driven by a 6.0% change in the company's P/E Multiple.| 9282025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 316.98 | 349.88 | 10.38% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 189254.00 | 194820.00 | 2.94% |
| Net Income Margin (%) | 2.83% | 2.84% | 0.28% |
| P/E Multiple | 13.32 | 14.12 | 6.03% |
| Shares Outstanding (Mil) | 225.20 | 223.30 | 0.84% |
| Cumulative Contribution | 10.37% |
Market Drivers
9/28/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| ELV | 10.4% | |
| Market (SPY) | 4.3% | 21.9% |
| Sector (XLV) | 15.2% | 52.7% |
Fundamental Drivers
The -7.3% change in ELV stock from 6/29/2025 to 12/28/2025 was primarily driven by a -12.1% change in the company's Net Income Margin (%).| 6292025 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 377.47 | 349.88 | -7.31% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 183124.00 | 194820.00 | 6.39% |
| Net Income Margin (%) | 3.23% | 2.84% | -12.10% |
| P/E Multiple | 14.44 | 14.12 | -2.23% |
| Shares Outstanding (Mil) | 226.40 | 223.30 | 1.37% |
| Cumulative Contribution | -7.33% |
Market Drivers
6/29/2025 to 12/28/2025| Return | Correlation | |
|---|---|---|
| ELV | -7.3% | |
| Market (SPY) | 12.6% | 10.6% |
| Sector (XLV) | 17.0% | 51.7% |
Fundamental Drivers
The -3.9% change in ELV stock from 12/28/2024 to 12/28/2025 was primarily driven by a -23.0% change in the company's Net Income Margin (%).| 12282024 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 364.03 | 349.88 | -3.89% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 174015.00 | 194820.00 | 11.96% |
| Net Income Margin (%) | 3.69% | 2.84% | -23.00% |
| P/E Multiple | 13.15 | 14.12 | 7.35% |
| Shares Outstanding (Mil) | 231.90 | 223.30 | 3.71% |
| Cumulative Contribution | -4.02% |
Market Drivers
12/28/2024 to 12/28/2025| Return | Correlation | |
|---|---|---|
| ELV | -3.9% | |
| Market (SPY) | 17.0% | 9.0% |
| Sector (XLV) | 13.8% | 52.1% |
Fundamental Drivers
The -28.6% change in ELV stock from 12/29/2022 to 12/28/2025 was primarily driven by a -30.0% change in the company's Net Income Margin (%).| 12292022 | 12282025 | Change | |
|---|---|---|---|
| Stock Price ($) | 490.16 | 349.88 | -28.62% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 153247.00 | 194820.00 | 27.13% |
| Net Income Margin (%) | 4.06% | 2.84% | -30.03% |
| P/E Multiple | 18.88 | 14.12 | -25.22% |
| Shares Outstanding (Mil) | 239.60 | 223.30 | 6.80% |
| Cumulative Contribution | -28.95% |
Market Drivers
12/29/2023 to 12/28/2025| Return | Correlation | |
|---|---|---|
| ELV | -23.4% | |
| Market (SPY) | 48.4% | 12.1% |
| Sector (XLV) | 17.8% | 50.9% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ELV Return | 8% | 46% | 12% | -7% | -21% | -5% | 23% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| ELV Win Rate | 58% | 58% | 50% | 33% | 67% | 67% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| ELV Max Drawdown | -42% | -10% | -8% | -19% | -21% | -25% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | ELV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -24.3% | -25.4% |
| % Gain to Breakeven | 32.0% | 34.1% |
| Time to Breakeven | 310 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -43.2% | -33.9% |
| % Gain to Breakeven | 76.2% | 51.3% |
| Time to Breakeven | 214 days | 148 days |
| 2018 Correction | ||
| % Loss | -25.6% | -19.8% |
| % Gain to Breakeven | 34.4% | 24.7% |
| Time to Breakeven | 567 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -67.2% | -56.8% |
| % Gain to Breakeven | 204.8% | 131.3% |
| Time to Breakeven | 1,821 days | 1,480 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Elevance Health's stock fell -24.3% during the 2022 Inflation Shock from a high on 10/31/2022. A -24.3% loss requires a 32.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Elevance Health (ELV):
- State Farm for health insurance.
- JPMorgan Chase for health benefits and services.
AI Analysis | Feedback
- Health Benefit Plans: Provides a comprehensive range of health insurance plans for employer groups, individuals, and government-sponsored programs like Medicare and Medicaid.
- Pharmacy Benefits Management (CarelonRx): Manages prescription drug benefits, including formulary management, drug utilization review, and claims processing for health plan members.
- Healthcare Services and Solutions (Carelon): Offers care delivery and management services such as behavioral health, complex care management, home-based care, and advanced analytics for healthcare providers and payers.
AI Analysis | Feedback
Elevance Health (ELV) operates primarily as a health benefits company, serving a broad spectrum of individuals through various channels. Given the diversified nature of its customer base rather than reliance on a few major corporate clients, its customers can be best understood through the following categories:
-
Employer Groups (Commercial Market): Elevance Health provides health insurance plans to a vast number of large, medium, and small businesses across the United States. These businesses choose Elevance Health plans to offer health benefits to their employees. While these are companies, Elevance Health's commercial business is highly diversified, with no single employer group representing a major identifiable customer that would typically be disclosed.
-
Government-Sponsored Programs: This significant segment involves partnerships with government entities to administer health benefits for specific populations. Key programs include:
- Medicaid: Elevance Health contracts with state governments to provide healthcare services for low-income individuals and families. The states are the primary contracting customers in this instance.
- Medicare Advantage: Elevance Health offers private health plans to eligible seniors and other beneficiaries under the federal Medicare program. While individuals enroll in these plans, the Centers for Medicare & Medicaid Services (CMS) is the overarching federal entity that contracts with private insurers like Elevance.
- Federal Employee Program (FEP): Administering health benefits for federal employees, retirees, and their dependents in partnership with the Office of Personnel Management (OPM).
-
Direct Individual & Family Purchasers: Elevance Health also offers health insurance plans directly to individuals and families who purchase coverage outside of an employer or government program. These plans are available through public health insurance marketplaces (exchanges) established under the Affordable Care Act, as well as directly from Elevance Health (off-exchange).
AI Analysis | Feedback
- CVS Health (CVS)
- Walgreens Boots Alliance (WBA)
- Walmart Inc. (WMT)
- Alphabet Inc. (GOOGL)
- Palantir Technologies Inc. (PLTR)
AI Analysis | Feedback
Gail K. Boudreaux, President & CEO
Ms. Boudreaux has over three decades of deep expertise in the healthcare industry, serving as President and Chief Executive Officer of Elevance Health since November 2017. Prior to joining Elevance Health (formerly Anthem, Inc.), she was the Chief Executive Officer of UnitedHealthcare, the largest business division of UnitedHealth Group, where she was responsible for approximately $120 billion in revenue and managed over 60,000 employees serving 45 million consumers. Earlier in her career, she served as Executive Vice President of Health Care Services Corporation and President of Blue Cross/Blue Shield of Illinois. In 2015, Ms. Boudreaux founded and became CEO of GKB Global Health, LLC, a healthcare strategy and business advisory firm. She has also served on the boards of directors for other public companies such as Target, Novavax, and Xcel Energy.
Mark Kaye, Executive Vice President & CFO
Mr. Kaye was named Executive Vice President and Chief Financial Officer of Elevance Health, with full responsibility for the role commencing November 1, 2023. He joined Elevance Health from Moody's Corporation, where he served as Chief Financial Officer, overseeing all global finance activities. Before his time at Moody's, Mr. Kaye held various leadership roles in strategic finance, financial planning and analysis, and large-scale project management at companies including MassMutual Life Insurance Company and Voya Financial.
Peter D. Haytaian, Executive Vice President; President of Carelon and CarelonRx
Mr. Haytaian serves as Executive Vice President of Elevance Health and President for Carelon and CarelonRx, where he is responsible for the strategic direction, performance, and growth of Carelon's diversified assets and services, including pharmacy, behavioral health, complex and chronic care, and advanced analytics. He previously held roles at Elevance Health as Executive Vice President and President of Commercial Health Benefits, and Executive Vice President and President of Government Health Benefits. His prior experience also includes serving as Chief Executive Officer of the Northeastern Region at Amerigroup Corp. and President and Chief Executive Officer of Amerigroup New Jersey Inc.
Felicia F. Norwood, Executive Vice President & President of Government Health Benefits
Ms. Norwood holds the position of Executive Vice President and President of Government Health Benefits at Elevance Health. In this role, she is responsible for the strategic direction and all operations related to the company's Medicaid, Medicare, and federal government solutions businesses.
Morgan Kendrick, Executive Vice President & President of Commercial and Specialty Health Benefits
Mr. Kendrick has been with Elevance Health (and its affiliated companies) since 1995 and has served as President of the Commercial and Specialty Business Division since October 2021.
AI Analysis | Feedback
Here are the key risks to Elevance Health (ELV):- Rising Healthcare Costs and Medical Expenses: Elevance Health faces significant challenges from increasing medical expenses and rising healthcare utilization, particularly within its Medicare Advantage and Medicaid plans. This trend directly impacts the company's margins and overall profitability. The company has indicated that it expects a decline in Medicaid margins as state payment rates frequently do not adequately cover members' medical costs.
- Regulatory Changes and Scrutiny: The highly regulated healthcare industry exposes Elevance Health to substantial risks from changes in federal and state regulations. Modifications to policies related to Medicare Advantage, Medicaid, and the Affordable Care Act (ACA) can significantly affect the company's operations, revenue, and profitability. Specific concerns include potential increased oversight and Senate hearings concerning Medicare Advantage, stricter reporting requirements, and the anticipated expiration of enhanced premium tax credits for ACA plans. Furthermore, ongoing investigations into potential securities law violations underscore the company's exposure to regulatory and compliance risks.
- Medicaid Membership Fluctuations and Redeterminations: The reduction in the total number of Medicaid members, largely due to state-initiated redeterminations of eligibility, is directly impacting Elevance Health's membership numbers and financial margins. This trend has also led to a sicker pool of remaining Medicaid members, which in turn drives up healthcare costs for the company. There is also a potential for a notable contraction in the ACA marketplace if enhanced subsidies expire, further contributing to membership-related risks.
AI Analysis | Feedback
- Increased regulatory scrutiny and potential reform of Pharmacy Benefit Managers (PBMs). Elevance Health operates CarelonRx, a significant PBM. There is substantial bipartisan legislative and regulatory momentum in the U.S. to increase transparency, regulate PBM practices, and potentially delink PBM compensation from drug prices, which could directly impact a substantial revenue and profit stream for ELV.
- Expansion of non-traditional players (tech and retail giants) into healthcare delivery and pharmacy services. Companies like Amazon (e.g., One Medical, RxPass), Walmart (e.g., health clinics), and CVS Health (e.g., Signify Health, Oak Street Health) are aggressively expanding their footprint across primary care, urgent care, pharmacy, and home health. While not directly replacing insurance plans, these players aim to control more aspects of the healthcare value chain, potentially disintermediating traditional insurers from parts of the care delivery process, influencing member choice, and creating new, integrated models that could bypass or reduce the role of traditional insurers.
AI Analysis | Feedback
Elevance Health (symbol: ELV) operates within several significant addressable markets in the United States, primarily focusing on health insurance, pharmacy benefit management, and care management solutions.
For its health insurance products and services, which include commercial, Medicare, Medicaid, and individual plans, the U.S. health insurance market demonstrates substantial size. The U.S. health insurance market was valued at approximately USD 1.23 trillion in 2024 and is projected to reach USD 1.77 trillion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 6.98%. Other estimates place the U.S. health insurance market size at USD 453 billion in 2024, expected to reach USD 639 billion by 2033 with a CAGR of 3.7% from 2025-2033. Another report indicates the U.S. health insurance market was valued at USD 613.0 billion in 2024 and is expected to increase to USD 1161.7 billion by 2032, advancing at a CAGR of 8.5% during 2025–2032. The broader U.S. managed care market, encompassing Medicare, Medicaid, and private health insurance, is forecasted to reach US$4.37 trillion in 2028, with a CAGR of 6.09% from 2024 to 2028. Elevance Health is a leading player in this sector, holding an exclusive license for the Blue Cross Blue Shield brand in 14 states and insuring approximately one out of every three people in these licensed states.
In the realm of pharmacy benefit management (PBM), a key service offered by Elevance Health, the U.S. market is also considerable. The U.S. pharmacy benefit management market size was valued at USD 482.4 billion in 2022 and is expected to expand at a CAGR of 8.77% from 2023 to 2030, reaching USD 934.0 billion by 2030. Other analyses show the U.S. PBM market valued at USD 587.4 billion in 2024, projected to be USD 638.0 billion in 2025. Another estimate for the U.S. pharmacy benefit management market size was USD 419.14 billion in 2024, with a projection to reach around USD 1,041.11 billion by 2034 at a CAGR of 9.53% from 2025 to 2034.
Elevance Health also provides care management solutions, and the U.S. market for these services is growing. The U.S. care management solutions market size was valued at USD 6.63 billion in 2024 and is projected to grow at a CAGR of 14.1% from 2025 to 2030, reaching USD 14.50 billion by 2030. Another assessment places the U.S. care management solutions market size at USD 4.43 billion in 2024, predicted to be worth approximately USD 16.30 billion by 2034, expanding at a CAGR of 13.9% from 2025 to 2034.
AI Analysis | Feedback
Elevance Health (ELV) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
-
Growth in Health Benefits Business: The company anticipates revenue growth from higher premium yields and rate adjustments within its Health Benefits segment. This includes targeted expansion in profitable areas such as Medicare Advantage, with expectations for high single-digit growth in individual Medicare Advantage and double-digit growth in group Medicare Advantage by 2025. Elevance Health also sees growth in its BlueCard and Affordable Care Act (ACA) membership.
-
Expansion of Carelon Segment and Healthcare Services: Elevance Health is focused on scaling its Carelon segment, which includes CarelonRx and Carelon Services. This involves continued growth in pharmacy customers and expanding value-based care solutions. Recent acquisitions, such as BioPlus and CareBridge, are integral to enhancing and expanding home-based and pharmacy services, contributing to double-digit top-line growth in CarelonRx.
-
Strategic Acquisitions: Future revenue will also be bolstered by strategic acquisitions. The company has cited the impact of the BioPlus acquisition and the CareBridge acquisition in expanding its service offerings and customer base. The acquisition of Blue Cross and Blue Shield of Louisiana is also expected to contribute to growth once finalized.
-
Improving Medicare Advantage Star Ratings: Elevance Health is making significant investments and efforts to improve its Medicare Advantage Star ratings. The goal is to have approximately 55% of its Medicare Advantage members in 4-Star or higher contracts for the 2027 payment year, a substantial increase from previous levels. Higher Star ratings are crucial for member retention, attracting new members, and enhancing reimbursement from the Centers for Medicare & Medicaid Services (CMS).
-
Digital and AI Innovation: Strategic investments in digital innovation and artificial intelligence (AI) are expected to drive long-term efficiency and improve the member experience. Initiatives include developing HealthOS, AI-enabled clinical support, and digital virtual assistants. While primarily focused on optimizing costs and operational efficiency, these technological advancements can indirectly support revenue growth by improving the attractiveness and competitiveness of Elevance Health's offerings, leading to better member satisfaction and retention.
AI Analysis | Feedback
Share Repurchases
- Elevance Health repurchased $2.9 billion of common stock in 2024.
- As of December 31, 2024, the company had approximately $9.3 billion of Board-approved share repurchase authorization remaining.
- In 2023, the company repurchased $2.7 billion of common stock.
Share Issuance
- The number of shares outstanding for Elevance Health has consistently declined over the last few years, indicating that repurchases have generally outweighed any issuances.
Outbound Investments
- In February 2025, Elevance Health acquired Granular Insurance, a risk management solution for self-funded insurers, and in January 2025, it acquired Indiana University Health's insurance business.
- Elevance Health plans to acquire Blue Cross and Blue Shield of Louisiana, which is expected to significantly enhance its market position in Louisiana.
- Notable acquisitions include BioPlus in 2023, a specialty pharmacy business, and Paragon Healthcare in 2024, which operates ambulatory infusion centers, both bolstering its Carelon segment.
Capital Expenditures
- Elevance Health's capital expenditures were approximately $1.26 billion in 2024 and $1.30 billion in 2023.
- The primary focus of capital expenditures includes improving clinical quality, member experience, behavioral health initiatives, and care coordination within its Carelon segment.
- Investments are also directed towards technology, including AI and digital strategy, to enhance efficiency and reduce operational costs.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ELV. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Elevance Health
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 175.78 |
| Mkt Cap | 181.5 |
| Rev LTM | 61,549 |
| Op Inc LTM | 11,544 |
| FCF LTM | 7,810 |
| FCF 3Y Avg | 8,024 |
| CFO LTM | 9,198 |
| CFO 3Y Avg | 9,508 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.4% |
| Rev Chg 3Y Avg | 3.2% |
| Rev Chg Q | 9.4% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | 17.7% |
| Op Mgn 3Y Avg | 16.4% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 14.6% |
| CFO/Rev 3Y Avg | 17.1% |
| FCF/Rev LTM | 11.6% |
| FCF/Rev 3Y Avg | 12.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 181.5 |
| P/S | 2.7 |
| P/EBIT | 21.2 |
| P/E | 33.0 |
| P/CFO | 18.5 |
| Total Yield | 5.2% |
| Dividend Yield | 2.1% |
| FCF Yield 3Y Avg | 5.7% |
| D/E | 0.3 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.2% |
| 3M Rtn | 7.5% |
| 6M Rtn | 10.9% |
| 12M Rtn | 11.8% |
| 3Y Rtn | 73.5% |
| 1M Excs Rtn | -1.1% |
| 3M Excs Rtn | 3.2% |
| 6M Excs Rtn | -1.3% |
| 12M Excs Rtn | -4.6% |
| 3Y Excs Rtn | -6.2% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Health Benefits | 148,571 | 138,484 | |||
| CarelonRx | 33,835 | 28,526 | 25,431 | 10,384 | 2,007 |
| Carelon Services | 14,147 | 12,860 | |||
| Net investment income | 1,825 | 1,485 | 1,378 | 877 | 1,005 |
| Corporate & Other | 479 | 399 | |||
| Net losses on financial instruments | -694 | -550 | 318 | 182 | 67 |
| Eliminations | -26,823 | -24,609 | -20,466 | ||
| Commercial and Specialty Business | 38,809 | 36,699 | 37,421 | ||
| Government Business | 82,919 | 71,572 | 62,632 | ||
| Other | 10,250 | 2,153 | 1,081 | ||
| Total | 171,340 | 156,595 | 138,639 | 121,867 | 104,213 |
Price Behavior
| Market Price | $349.88 | |
| Market Cap ($ Bil) | 78.1 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -21.5% | |
| 50 Days | 200 Days | |
| DMA Price | $333.46 | $351.57 |
| DMA Trend | down | up |
| Distance from DMA | 4.9% | -0.5% |
| 3M | 1YR | |
| Volatility | 29.7% | 36.5% |
| Downside Capture | 70.97 | 13.75 |
| Upside Capture | 104.04 | 7.62 |
| Correlation (SPY) | 22.6% | 9.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.13 | 0.38 | 0.29 | 0.31 | 0.15 | 0.29 |
| Up Beta | -1.05 | -0.81 | -0.65 | 0.27 | 0.30 | 0.38 |
| Down Beta | -0.49 | 0.56 | 0.58 | 0.61 | 0.10 | 0.22 |
| Up Capture | 93% | 74% | 51% | -2% | -4% | 3% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 11 | 20 | 33 | 62 | 128 | 383 |
| Down Capture | 25% | 53% | 31% | 44% | 16% | 63% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 8 | 21 | 29 | 63 | 120 | 367 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of ELV With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| ELV | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -2.5% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.2% |
| Annualized Volatility | 36.1% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | -0.00 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 52.2% | 9.3% | -3.4% | -12.2% | 22.4% | 1.3% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of ELV With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| ELV | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 3.6% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 27.6% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.6% |
| Sharpe Ratio | 0.15 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 56.4% | 27.4% | 1.8% | 4.4% | 27.2% | 6.6% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of ELV With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| ELV | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 11.2% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 30.3% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.41 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 65.5% | 48.2% | -0.3% | 16.5% | 42.6% | 7.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/21/2025 | -1.2% | -3.3% | -8.3% |
| 7/17/2025 | -12.2% | -13.9% | -14.3% |
| 4/22/2025 | 2.3% | 1.8% | 1.4% |
| 1/23/2025 | 2.7% | 2.4% | -1.4% |
| 10/17/2024 | -10.6% | -16.4% | -18.1% |
| 4/18/2024 | 3.2% | 4.9% | 6.9% |
| 1/24/2024 | 0.3% | 4.3% | 8.5% |
| 10/18/2023 | 0.8% | -2.8% | -1.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 10 | 11 |
| # Negative | 10 | 12 | 11 |
| Median Positive | 3.0% | 4.4% | 3.4% |
| Median Negative | -5.7% | -3.8% | -4.8% |
| Max Positive | 7.7% | 10.8% | 9.1% |
| Max Negative | -12.2% | -16.4% | -18.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 10212025 | 10-Q 9/30/2025 |
| 6302025 | 7172025 | 10-Q 6/30/2025 |
| 3312025 | 4222025 | 10-Q 3/31/2025 |
| 12312024 | 2202025 | 10-K 12/31/2024 |
| 9302024 | 10172024 | 10-Q 9/30/2024 |
| 6302024 | 7172024 | 10-Q 6/30/2024 |
| 3312024 | 4182024 | 10-Q 3/31/2024 |
| 12312023 | 2212024 | 10-K 12/31/2023 |
| 9302023 | 10182023 | 10-Q 9/30/2023 |
| 6302023 | 7192023 | 10-Q 6/30/2023 |
| 3312023 | 4192023 | 10-Q 3/31/2023 |
| 12312022 | 2152023 | 10-K 12/31/2022 |
| 9302022 | 10192022 | 10-Q 9/30/2022 |
| 6302022 | 7202022 | 10-Q 6/30/2022 |
| 3312022 | 4202022 | 10-Q 3/31/2022 |
| 12312021 | 2162022 | 10-K 12/31/2021 |
Insider Activity
Expand for More| Owner | Title | Filing Date | Action | Price | Shares | TransactedValue | Value ofHeld Shares | Form | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | DeVore Susan D. | 8212025 | Buy | 312.15 | 1,200 | 374,580 | 1,093,149 | Form | |
| 1 | BOUDREAUX GAIL | President and CEO | 7182025 | Buy | 286.07 | 2,334 | 667,687 | 41,438,384 | Form |
| 2 | Kaye Mark | EVP & CFO | 4252025 | Sell | 424.82 | 4,588 | 1,949,074 | 8,061,809 | Form |
| 3 | Penczek Ronald W | CAO & Controller | 3112025 | Sell | 415.13 | 443 | 183,903 | 766,745 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.